CTLA-4 tail fusion enhances CAR-T anti-tumor immunity [bulk RNA-seq]
To gain further insight into how CCT fusion engineering impacts their function, we characterized CAR-T cells using transcriptome profiling. We performed mRNA-seq from all four groups of CAR-T cells, either without stimulation (baseline) or with 2 rounds of NALM6GL stimulation. For CAR-T cells that were cocultured with 2 rounds of NALM6GL cells, we sorted the pure CAR-T populations (CAR+; GFP-) before subjecting them to RNA sequencing Overall design: Bulk RNA sequencing of anti-CD22 CAR-T cells with 0 or 2 rounds of NALM6GL stimulation. In each treatment, there were four different CAR-T groups with three biological repeats per group.